Oxford Science Enterprises

Oxford Science Enterprises (OSE) is a venture capital firm deeply integrated with the University of Oxford, focusing on commercializing breakthrough scientific innovations. With a portfolio valued at over £2 billion, OSE invests in three core sectors: Life Sciences, Deep Tech, and Health Tech. It has partnered with over 200 leading academics from the university to build and support more than 80 high-impact companies. OSE’s strategy is to support early-stage ventures with long-term capital and hands-on expertise. Their investments span from biotechnology to quantum computing, with notable companies like Oxford Quantum Circuits, Ultromics, and Evox Therapeutics in the portfolio. OSE’s commitment to groundbreaking technologies is further emphasized by their mission to address global challenges such as health, food security, and sustainability. The firm is led by a distinguished team with deep ties to Oxford’s innovation ecosystem, including Jack Edmondson, the Chief Investment Officer, who has extensive experience managing large-scale investments at Oxford University Endowment Management. This alignment with Oxford enables OSE to identify and scale cutting-edge research into successful businesses. OSE’s model is designed to bridge the gap between academic discovery and market application, creating transformative companies that aim to improve human lives and drive future technological advancements.